跳到主要导航
跳到搜索
跳到主要内容
Pure University (For Demo Only) 国内
帮助和常见问题
English
中文
国内
简介
研究单位
科研成果
设备
数据集
活动
奖项
影响
项目
新闻 / 媒体
按专业知识、名称或附属进行搜索
联系专家
查看 Scopus 资料
Camfield Peter R.
Professor
Dalhousie University
,
Psychology
电子邮件
CP156523
dal
ca
网站
https://www.scopus.com/authid/detail.url?authorId=7005156523
h-index
h10-index
h5-index
11700
引用
64
H-指数
根据存储在 Pure 中的刊物数量以及来自 PlumX 的引用文献数量进行计算
986
引用
15
H-指数
根据储存在 Pure 的刊物以及来自 Scopus 的引用文献数量计算
42
引用
2
H-指数
根据储存在 Pure 的刊物以及来自 Scopus 的引用文献数量计算
1977 …
2022
每年的科研成果
综述
指纹
网络
科研成果
(272)
相似简介
(6)
指纹
深入其中 Camfield Peter R. 为活跃的研究主题。这些主题标签来自此人的成果。它们共同形成唯一的指纹。
分类
加权
按字母排序
Medicine and Dentistry
Epileptic Seizure
100%
Benign Childhood Epilepsy
35%
Anticonvulsant
32%
Pediatrics
31%
Febrile Seizure
27%
Disease
26%
Drug Therapy
25%
Epilepsy Syndromes
22%
Pediatric Neurology
22%
Pediatric Epilepsy
21%
Severe Myoclonic Epilepsy of Infancy
21%
Epileptic Absence
19%
Rolandic Epilepsy
17%
Quality of Life
17%
Status Epilepticus
16%
Ceroid
15%
Intractable Epilepsy
13%
Recurrent Disease
11%
Pain Assessment
11%
Partial Seizure
11%
Tonic-Clonic Seizure
10%
Neurology
9%
Disease Course
9%
Infantile Spasm
9%
Population Research
9%
Epilepsy in Children
8%
Phenobarbital
8%
Scoring System
8%
Seizure Types
8%
Health Care
7%
Sudden Unexpected Death in Epilepsy
7%
Neurologic Disease
7%
Epilepsy
7%
Complex Partial Seizure
6%
Placebo
6%
Faintness
6%
Symptomatic Epilepsy
6%
Checklist
6%
Symptom
6%
Pediatrician
6%
Learning Disorder
6%
Cohort Analysis
5%
Physical Examination
5%
Adult Health
5%
Health Care Provider
5%
Lafora Disease
5%
Generalised Epilepsy
5%
Diagnosis
5%
Ethosuximide
5%
Transition to Adult Care
5%
Pharmacology, Toxicology and Pharmaceutical Science
Anticonvulsive Agent
74%
Remission
43%
Febrile Convulsion
38%
Benign Childhood Epilepsy
38%
Syndrome
24%
Recurrent Disease
24%
Pharmacotherapy
24%
Disease
19%
Intractable Epilepsy
19%
Carbamazepine
18%
Myoclonus Epilepsy
15%
Phenobarbital
14%
Tonic Clonic Seizure
13%
Symptom
11%
Agrotis
10%
Epileptic State
10%
Severe Myoclonic Epilepsy in Infancy
9%
Symptomatic Epilepsy
9%
Prospective Study
9%
Prevalence
9%
Adverse Event
9%
Placebo
9%
Focal Epilepsy
8%
Head Injury
8%
Apnea
8%
Ceroid
8%
Side Effect
8%
Diazepam
7%
Childhood Absence Epilepsy
7%
Epilepsy
6%
Phenytoin
6%
Anticonvulsant Therapy
6%
Antipyretic Agent
6%
Epileptic Absence
5%
Population Study
5%
Benzodiazepine
5%
Injury
5%
Sudden Infant Death Syndrome
5%
Recurrence Risk
5%
Rolandic Epilepsy
5%
Keyphrases
Childhood Epilepsy
47%
Epilepsy
41%
Seizure
25%
Febrile Seizures
19%
Remission
18%
Phenobarbital
15%
Population-based Study
13%
Nova Scotia
13%
Ceroid
12%
Antiepileptic Treatment
10%
Batten
10%
Carbamazepine
9%
Antiepileptic Drugs
9%
Pediatric Epilepsy
8%
Benign Familial Infantile Epilepsy
8%
Adolescents with Epilepsy
8%
Anticonvulsant Therapy
8%
Seizure-free
8%
Population-based
7%
Social Outcomes
7%
Generalized Tonic-clonic Seizures
7%
Transition Program
7%
Observational Pain Scale
7%
Antipyretic
7%
Pediatric Neurologist
7%
Epilepsy in children
6%
Epilepsy Treatment
6%
Adult Health Care
6%
Lennox-Gastaut Syndrome
6%
Cryptogenic Epilepsy
6%
Status Epilepticus
6%
Transition Clinic
6%
Epilepsy Syndrome
6%
Intractable Seizures
6%
Seizure Control
6%
Intractable Epilepsy
6%
Generalized Seizures
5%
Generalized Epilepsy
5%
Clinical Seizure
5%
Brain Injury
5%
Canada
5%
Intellectual Disability
5%
Placebo
5%
Pain Behavior
5%
Success Probability
5%
Benign Epilepsy
5%
Anticonvulsant
5%
Seizures in children
5%
Atypical Absence
5%
First Antiepileptic Drug
5%
